Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 15/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAG | P20916 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479268 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL16661864 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL19772824 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL19508734 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL17777238 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL19491793 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL17777179 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL19508731 | 0.85 | SELE (0.79) | SELE | |
| SCHEMBL23943292 | 0.84 | SELE (0.57) | SELEMAG | |
| SCHEMBL21993227 | 0.84 | SELE (0.58) | SELEMAPK1MAGALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519181-B2 | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors | GLYCOMIMETICS, INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519181-B2 | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors | CXCL12, CXCR4, SELE | SELE 3/4885MAPK1 2477/4885MAG 2339/4885 |
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885MAPK1 2477/4885MAG 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.